47 results about "Palonosetron" patented technology

Methods are provided to teat post-operative nausea and vomiting, as well as emeses generally, with 5-HT3 receptor antagonists. In particular, the invention discloses methods for reducing post-operative nausea and vomiting and other emetic events with palonosetron.

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

The invention relates to a preparation method of S-3-aminoquinuclidine dihydrochloride which is obtained by taking 3-aminoquinuclidine dihydrochloride as a raw material and carrying out resolving, salifying by resolving, recrystallizing, resolving, salifying, decoloring and crystallizing by concentration. The S-3-aminoquinuclidine dihydrochloride serves as an important raw material for preparing palonosetron. In the method, the 3-aminoquinuclidine dihydrochloride is taken as the raw material and is directly subjected to chiral acid resolution in proper solvent without derivation, with resolution ratio over 40% and optical purity over 98%. The method has simple synthetic method and low production cost, has total product yield over 35% and can be used for industrial production.

The present invention provides a pharmaceutical composition for delivering palonosetron through the buccal mucosa or sublingual mucosa. The pharmaceutical composition comprises 0.05-35% (w / w) of palonosetron, 40-90% of a film forming agent, 1-10% (w / w) of a plasticizer, 5-25% (w / v) of an adhesive agent, and 0.1-5% of a penetration enhancing agent. A preferred plasticizer is a polysorbate. A preferred adhesive agent is polyvinylpyrrolidone or carboxymethylcellulose. A preferred penetration enhancing agent is peppermint oil or menthol.

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

The invention belongs to the technical field of medicines and relates to a percutaneous-absorption palonosetron patch and a preparation method thereof. The patch is composed of a backing layer, a medicine-carrying pressure-sensitive adhesive layer and an anti-sticking layer; the medicine-carrying pressure-sensitive adhesive layer comprises a beta-cyclodextrin inclusion compound of palonosetron free alkali, a pressure-sensitive adhesive and a percutaneous absorption enhancer, wherein the beta-cyclodextrin inclusion compound of the palonosetron free alkali accounts for 4.78%-20.09% of the total weight, preferably 9%-19%, the pressure-sensitive adhesive accounts for 68.80%-95.22% of the total weight and the percutaneous absorption enhancer accounts for 0-11.11wt% of the total weight. In the beta-cyclodextrin inclusion compound of the palonosetron free alkali, the ratio of the palonosetron free alkali to the beta-cyclodextrin inclusion compound is 1: (1-3). The percutaneous-absorption palonosetron patch is provided with the beta-cyclodextrin inclusion compound of the palonosetron free alkali, and therefore, compared with a patch with non-inclusion medicine, the slow release of the medicine within 7 days is realized.

The invention relates to the technical field of biological medicine, in particular to a palonosetron oral cavity membrane preparation and a preparation method thereof. The palonosetron oral cavity membrane preparation and the preparation method thereof have the following advantages: (1) the oral cavity membrane preparation overcomes the bitter taste of palonosetron, has a good mouthfeel, and is completely dissolved and absorbed so that a patient can easily accept the palonosetron, and the oral cavity membrane preparation can be taken in any occasion without water, and is particularly suitable for patients who undergo chemotherapy and possibly vomit if drinking water; (2) the palonosetron oral cavity membrane preparation can quickly release a medicine and has the characteristics of quick effect acting and quick release; and (3) the palonosetron oral cavity membrane preparation is simple in production process and low in cost and is convenient to carry.

Methods are provided to treat post-operative nausea and vomiting, as well as emesis generally, with 5-HT3 receptor antagonists. In particular, the invention discloses methods for reducing post-operative nausea and vomiting and other emetic events with palonosetron.

The invention belongs to the technical field of medicine, and relates to a palonosetron percutaneous absorption patch and a preparation method thereof. The patch of the invention is composed of a backing layer, a drug-loaded pressure-sensitive adhesive layer and an anti-adhesive layer; Absorption enhancer. Wherein the β-cyclodextrin inclusion complex of palonosetron free base accounts for 4.78%-20.09% of the total weight, preferably 9%-19%, the pressure-sensitive adhesive accounts for 68.80%-95.22% by weight, and the transdermal absorption accelerator Accounting for 0~11.11wt% of the total weight. In the β-cyclodextrin inclusion compound of palonosetron free base, the ratio of the palonosetron free base to the β-cyclodextrin inclusion compound is 1:1-3. The palonosetron percutaneous absorption patch provided by the present invention is selected from the β-cyclodextrin inclusion complex of palonosetron free base, which successfully achieves a drug-free absorption within 7 days compared with the drug-unincluded patch. Release slowly.

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

The invention relates to a solid medicine composition comprising palonosetron. The solid medicine composition comprising the palonosetron comprises the palonosetron or pharmaceutical salt and a pharmaceutically acceptable excipient thereof, and does not contain an adhesive.

Provided are a pharmaceutical composition with improved stability including palonosetron, a preparation method thereof, and a pharmaceutical package including the pharmaceutical composition.

A method for treating chemotherapy-induced nausea and vomiting in individuals undergoing chemotherapy and previously treated with, and whom failed to respond to, a 5-HT3 antagonist other than granisetron is described. Individuals who fail to respond to, for example, palonosetron, as evidenced by an inadequate prevention or attenuation of acute or delayed chemotherapy-induced nausea and vomiting, are treated with a semi-solid drug delivery vehicle that provides a sustained release of granisetron.